Bryn Mawr Hospital, a member of Main Line Health’s Lankenau Heart Institute, is the first in Pennsylvania to offer adult patients with moderate to severe central sleep apnea with the newly approved remedē® System, a breakthrough treatment that has been shown to improve sleep, breathing and quality of life.
“We are thrilled to be the first commercial implant in Pennsylvania and, since market release, among the first commercial implants in the U.S. outside the FDA approval process to offer this new treatment option to patients suffering with moderate to severe central sleep apnea,” says Sheetal Chandhok, MD, Lankenau Heart Institute cardiologist and electrophysiologist at Bryn Mawr Hospital. “This implantable system can monitor and stabilize the breathing pattern to restore sleep throughout the night—offering critical benefits to patients’ overall cardiovascular health and quality of life.”
Patients who are suffering from central sleep apnea can experience many symptoms, including excessive daytime sleepiness, reduced exercise capacity, hypoxia (decrease in blood oxygen level), and irregular or very fast heart rhythms (arrhythmia). Studies have shown that untreated central sleep apnea is a significant contributor to lowered quality of life and contributes to poor cardiovascular outcomes such as worsening heart failure.
The remedē® System stimulates a nerve in the chest—the phrenic nerve—to send signals to the diaphragm, the large muscle that controls breathing. These signals stimulate breathing in the same way that the brain would. The system is placed by a cardiologist during a minimally invasive outpatient procedure. The procedure typically takes an average of two to three hours and is performed under light sedation. Most patients are able to go home after a one-night stay in the hospital.
“Offering this new treatment option to patients with sleep apnea—a large population of patients in need of relief—truly reflects our commitment to advance cardiovascular care in our communities and throughout the Philadelphia region and beyond,” says William Gray, MD, Chief of Cardiovascular Diseases at Lankenau Heart Institute.